Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A different perspective regarding prostate-specific antigen testing: in reply.

Grady D, Redberg RF.

Arch Intern Med. 2012 Jul 23;172(14):1111. doi: 10.1001/archinternmed.2012.2637. No abstract available.

PMID:
22825065
2.

A different perspective regarding prostate-specific antigen testing.

Casner PR.

Arch Intern Med. 2012 Jul 23;172(14):1110-1. doi: 10.1001/archinternmed.2012.2038. No abstract available.

PMID:
22825064
3.

Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.

Shimizu F, Igarashi A, Fukuda T, Kawachi Y, Minowada S, Ohashi Y, Fujime M.

Jpn J Clin Oncol. 2007 Oct;37(10):763-74. Epub 2007 Oct 22.

PMID:
17956899
4.

Family physicians could help in predicting life expectancy without prostate cancer.

Mohan R.

J Clin Oncol. 2008 Feb 1;26(4):690-1; author reply 691-3. doi: 10.1200/JCO.2007.14.7108. No abstract available.

PMID:
18235137
5.

A 56-year-old physician who underwent a PSA test.

Bennett CL.

Arch Intern Med. 2012 Feb 27;172(4):311. doi: 10.1001/archinternmed.2011.2246. No abstract available.

PMID:
22371918
6.

Are we finally winning the war on cancer?

Cutler DM.

J Econ Perspect. 2008 Fall;22(4):3-26. No abstract available.

PMID:
19768842
7.

Quality of life and guidelines for PSA screening.

Sox HC.

N Engl J Med. 2012 Aug 16;367(7):669-71. doi: 10.1056/NEJMe1207165. No abstract available.

PMID:
22894580
8.

[Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].

SouliƩ M, Villers A, Richaud P, Prapotnich D, Ruffion A, Grosclaude P.

Prog Urol. 2001 Dec;11(6):1195-204. Review. French.

PMID:
11859652
9.

Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.

Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM.

Urology. 2004 Jan;63(1):103-9.

PMID:
14751359
10.

Stats & Facts. Prostate-specific antigen screening.

[No authors listed]

Manag Care Interface. 2001 Jul;14(7):40-1. No abstract available.

PMID:
11481814
11.

Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools.

McCloskey SA, Kuettel MR.

J Natl Compr Canc Netw. 2007 Aug;5(7):709-13. Review.

PMID:
17692176
12.

Feasibility of using guidelines to choose treatment for prostate cancer.

Mohan R, Beydoun H, Davis J, Lance R, Schellhammer P.

Can J Urol. 2010 Feb;17(1):4975-84.

PMID:
20156376
13.

Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.

Hoffman KE, Nguyen PL, Ng AK, D'Amico AV.

J Urol. 2010 May;183(5):1798-802. doi: 10.1016/j.juro.2010.01.002. Epub 2010 Mar 17.

PMID:
20299039
14.

The prostate cancer screening controversy in perspective.

Vaughn KW Jr.

Cleve Clin J Med. 1998 Oct;65(9):459-62.

PMID:
9795486
15.

Point: the value of predicting life expectancy in men with clinically localized prostate cancer.

Clayton DB, Urban DA.

J Natl Compr Canc Netw. 2007 Aug;5(7):703-8. Review.

PMID:
17692175
16.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate.

Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE.

Urology. 1995 Jul;46(1):2-13. No abstract available.

PMID:
7541583
17.

Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.

Svatek RS, Lotan Y.

Cancer Prev Res (Phila). 2011 Feb;4(2):277-83. doi: 10.1158/1940-6207.CAPR-10-0200. Epub 2010 Dec 16.

18.

Continued undertreatment of older men with localized prostate cancer.

Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD.

Urology. 2003 Nov;62(5):860-5.

PMID:
14624909
19.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

PMID:
11058616
20.

Screening for prostate cancer: the role of prostate-specific antigen.

Ferrer RL.

Md Med J. 1996 Nov;45(11):938-40. Review. No abstract available.

PMID:
8942171

Supplemental Content

Support Center